- Home
- NFJ vs CGEM Comparison
NFJ vs CGEM Comparison
Compare NFJ & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NFJ | CGEM |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2003 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NFJ | CGEM |
|---|---|---|
| Price | $15.68 | $22.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $30.13 |
| AVG Volume (30 Days) | 129.8K | ★ 669.9K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 9.01% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.25 | $5.68 |
| 52 Week High | $15.75 | $23.19 |
Technical Indicators
Market Signals| Indicator | NFJ | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 58.44 | 58.77 |
| Support Level | $14.87 | $11.87 |
| Resistance Level | $15.75 | $23.19 |
| Average True Range (ATR) | 0.14 | 1.01 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 79.96 | 55.78 |
Price Performance
Historical ComparisonAbout NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. The primary investment objective of the company is to seek current income and gains, with a secondary objective of long-term capital appreciation. It pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.